文献速递基础与转化研究临床试验与 GCP

烟酰胺增强自然杀伤细胞功能并使非霍奇金淋巴瘤患者获得缓解

Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma.
PubMed 文献 · Sci Transl Med · 2023-07-19

研究显示,用IL-15和烟酰胺(NAM)体外培养的NK细胞稳定诱导CD62L表达、增强细胞毒性和炎性细胞因子产生,并在异种移植中优先持续存在。首次人体1期试验中,GDA-201联合利妥昔单抗治疗19例晚期NHL患者总体缓解率为74%,13例完全缓解、1例部分缓解,GDA-201细胞在血液、骨髓和肿瘤组织中可检测至14天。

要点

  • IL-15和NAM体外培养的NK细胞稳定诱导CD62L表达并增强细胞毒性和炎性细胞因子产生。
  • GDA-201联合利妥昔单抗治疗19例晚期NHL患者总体缓解率为74%,其中13例完全缓解、1例部分缓解。
  • GDA-201细胞在血液、骨髓和肿瘤组织中可检测至14天并维持有利的代谢特征。

核心结论

  • GDA-201联合利妥昔单抗耐受良好,在19例晚期NHL患者中总体缓解率为74%,支持GDA-201作为癌症疗法进一步开发。

研究设计与样本

  • 体外研究:用IL-15和NAM体外培养NK细胞,评估CD62L诱导、FOXO1稳定性、代谢变化、细胞毒性和异种移植过继转移中的持续存在。
  • 首次人体1期临床试验(NCT03019666):测试IL-15和NAM体外扩增的NK细胞(GDA-201)联合单克隆抗体治疗复发或难治性非霍奇金淋巴瘤(NHL)和多发性骨髓瘤(MM)患者。

主要发现

  • 用IL-15和NAM体外培养的NK细胞稳定诱导CD62L表达,高频率CD62L与转录因子FOXO1升高相关,NAM通过防止蛋白酶体降解促进FOXO1稳定性。
  • 用NAM培养的NK细胞表现出与葡萄糖通量升高和抗氧化应激保护相关的代谢变化,并增强细胞毒性和炎性细胞因子产生,在异种过继转移实验中优先持续存在。
  • GDA-201联合利妥昔单抗治疗19例晚期NHL患者,总体缓解率为74%,其中13例完全缓解、1例部分缓解。
  • GDA-201细胞在血液、骨髓和肿瘤组织中可检测至14天,并维持有利的代谢特征。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic natural killer (NK) cell adoptive transfer has shown the potential to induce remissions in relapsed or refractory leukemias and lymphomas, but strategies to enhance NK cell survival and function are needed to improve clinical efficacy. Here, we demonstrated that NK cells cultured ex vivo with interleukin-15 (IL-15) and nicotinamide (NAM) exhibited stable induction of l-selectin (CD62L), a lymphocyte adhesion molecule important for lymph node homing. High frequencies of CD62L were associated with elevated transcription factor forkhead box O1 (FOXO1), and NAM promoted the stability of FOXO1 by preventing proteasomal degradation. NK cells cultured with NAM exhibited metabolic changes associated with elevated glucose flux and protection against oxidative stress. NK cells incubated with NAM also displayed enhanced cytotoxicity and inflammatory cytokine production and preferentially persisted in xenogeneic adoptive transfer experiments. We also conducted a first-in-human phase 1 clinical trial testing adoptive transfer of NK cells expanded ex vivo with IL-15 and NAM (GDA-201) combined with monoclonal antibodies in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) (NCT03019666). Cellular therapy with GDA-201 and rituximab was well tolerated and yielded an overall response rate of 74% in 19 patients with advanced NHL. Thirteen patients had a complete response, and 1 patient had a partial response. GDA-201 cells were detected for up to 14 days in blood, bone marrow, and tumor tissues and maintained a favorable metabolic profile. The safety and efficacy of GDA-201 in this study support further development as a cancer therapy.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Cichocki F, Zhang B, Wu CY, et al. Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma. Sci Transl Med. 2023. PMID: 37467318. doi:10.1126/scitranslmed.ade3341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。